Joan How

16PUBLICATIONS
83CO-AUTHORS
Haematological tumoursMolecular targetsPredictive and prognostic markersCardiology (incl. cardiovascular diseases)Forensic epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Aug 20, 2026
Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.

|Mar 04, 2026
Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms.

Orly Leiva, Steven Soo, Olivia C Liu

|Feb 26, 2026
Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.

Jonas S Jutzi, Edie Crosse, Chulwoo J Kim

|Feb 24, 2026
Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.

Benjamin Rolles, Cilomar Martins de Oliveira Filho, Nathan Fergusson

|Jan 07, 2026
Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms.

Orly Leiva, Steven Soo, Olivia C Liu

|Sep 18, 2024
Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis.

Rathnam K Venkat, Robert A Redd, Amyah C Harris

Pageof 3

Frequent Collaborators

7 joint publications

Gabriela S Hobbs

3 joint publications

Marlise R Luskin

3 joint publications

Lachelle D Weeks

3 joint publications

Anna E Marneth